|
Rosado-Jimenez L, Mestre-Terkemani Y, Garcia-Aliaga A, Marin-Vera M, Macias-Cerrolaza JA, Sarabia-Meseguer MD, Garcia-Hernandez MR, Zafra-Poves M, Sanchez-Henarejos P, Ayala de la Pena F, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. Recurrent genetic variants and prioritization of variants of uncertain clinical significance associated with hereditary breast and ovarian cancer in families from the Region of Murcia. Adv Lab Med. 2023 Sep 22;4(3):279-287. doi: 10.1515/almed-2023-0103. eCollection 2023 Sep. PubMed PMID: 38075165; PubMed Central PMCID: PMC10701504.
AÑO: 2023; IF: 1.0
|
38075165
|
Aguado de la Rosa C, Cruz Castellanos P, Lazaro-Quintela M, Domine M, Vazquez Estevez S, Lopez-Vivanco G, Firvida Perez JL, Alonso Romero JL, Ferrera Delgado L, Garcia Giron C, Diz Tain P, Alvarez Alvarez R, Mut Sanchis P, Fernandez Canton I, Manrique Abos I, Martinez Aguillo M, Gomez-Aldaravi Gutierrez L, Ortega Granados AL, Alvarez Cabellos R, Garcia Sebastian A, Garcia Sifuentes LF, Reguart N. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). Lung Cancer. 2022 Nov;173:83-93. doi: 10.1016/j.lungcan.2022.09.010. Epub 2022 Sep 19. PubMed PMID: 36162227.
AÑO: 2022; IF: 5.3
|
|
Antonio CCP, Alida GG, Elena GG, Rocio GS, Jeronimo MG, Luis ARJ, Anibal ND, Francisco BV, Jesus GRA, Pablo RR, Jose GM. Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial. Ann Surg Oncol. 2022 Apr;29(4):2617-2625. doi: 10.1245/s10434-021-11087-7. Epub 2021 Nov 23. PubMed PMID: 34812982.
AÑO: 2022; IF: 3.7
|
|
de la Cruz-Merino L, Gion M, Cruz J, Alonso-Romero JL, Quiroga V, Moreno F, Andres R, Santisteban M, Ramos M, Holgado E, Cortes J, Lopez-Miranda E, Cortes A, Henao F, Palazon-Carrion N, Rodriguez LM, Ceballos I, Soto A, Puertes A, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jimenez-Cortegana C, Sanchez-Margalet V, Rojo F. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study. BMC Cancer. 2022 Dec 3;22(1):1258. doi: 10.1186/s12885-022-10363-3. PubMed PMID: 36463104; PubMed Central PMCID: PMC9719636.
AÑO: 2022
|
|
Castillo-Guardiola V, Rosado-Jimenez L, Sarabia-Meseguer MD, Marin-Vera M, Macias-Cerrolaza JA, Garcia-Hernandez R, Zafra-Poves M, Sanchez-Henarejos P, Moreno-Locubiche MA, Cuevas-Tortosa E, Arnaldos-Carrillo M, Ayala de la Pena F, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance. Eur J Med Genet. 2022 Apr;65(4):104468. doi: 10.1016/j.ejmg.2022.104468. Epub 2022 Mar 1. PubMed PMID: 35245693.
AÑO: 2022; IF: 1.9
|